GHK-CU 100mg research peptide UK is the advanced bulk-format copper-binding tripeptide for high-throughput UK laboratory programmes requiring extended single-batch consistency. ≥98% HPLC-verified. Janoshik tested. Same-day UK dispatch before 4pm. For in-vitro research use only.
Safety Information: Not intended for human or veterinary use. Use appropriate laboratory safety procedures when handling.
GHK-CU 50mg should only be used in laboratory settings by qualified personnel.
Ensure all experimental procedures comply with local and institutional regulations.
This peptide is supplied for research and scientific study purposes only.
GHK-CU 100 mg:
Click here to View
Research use only • UK dispatch • Orders before 4pm ship same day • Secure checkout
GHK-CU 100mg Research Peptide UK
GHK-CU 100mg is the advanced bulk-format version of the most extensively documented copper-binding research peptide available from a UK supplier. Identical compound to the 50mg format — C14H23CuN6O4, 403.92 g/mol, naturally occurring copper-complexed tripeptide with documented interactions across over 4,000 human genes — providing double the compound volume for institutional research programmes, high-throughput studies, and multi-researcher laboratory settings requiring consistent compound supply over extended timelines.
The ghk-cu 100mg research format is appropriate when the 50mg pilot phase has validated the experimental design and the full programme requires sustained, batch-consistent compound supply. Single-batch operation is particularly important for longitudinal collagen synthesis studies, extended wound biology assays, and multi-time-point gene expression investigations where batch-to-batch molecular variation would introduce systematic error into time-series data. The 100mg format also suits institutional settings where multiple researchers access the same compound batch, ensuring CoA consistency across all users within a programme as a procurement and compliance requirement.
The primary research applications of ghk CU 100mg are identical to those documented for the 50mg format at expanded scale: collagen synthesis modulation in fibroblast models, extracellular matrix biology covering fibronectin and glycosaminoglycan research, antioxidant signalling (SOD and catalase pathways), wound biology assay design, and stem cell differentiation research. The 100mg format provides the volume for full dose-response gradients across multiple concentration arms — a capacity the 50mg format does not reliably support in high-arm-count study designs.
In skin and cellular biology research, GHK-CU 100mg and BPC-157 10mg are frequently studied in parallel. GHK-CU operates through copper-binding and extracellular matrix–associated signalling interactions and ECM pathway modulation; BPC-157 acts through nitric oxide and VEGF pathways. These mechanistically distinct probes can function as independent variables within the same cellular model. For pilot-scale research and full mechanism detail covering the 4,000-gene expression profile, see the GHK-CU 50mg research guide on the Ascend Peptides UK blog.
All batches were independently tested by Janoshik. HPLC greater than or equal to 98%. LC-MS confirmed. Verifiable CoA.
For laboratory handling purposes, GHK-Cu may be reconstituted using sterile aqueous solutions such as bacteriostatic water or saline, depending on experimental requirements.
DISCLAIMER: For in-vitro research only. Not an MHRA-licensed medicine.
A curated entry point for buyers comparing quality, documentation, and availability.
UK same-day dispatch – PCI-
compliant payments –
Laboratory research only
© 2026 by Ascend Peptides Uk.
